Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-25T06:33:57.640Z Has data issue: false hasContentIssue false

Case 13 - “My Mom Looks Like a Zombie!”

Antipsychotic-Related Movement Disorders

Published online by Cambridge University Press:  31 October 2024

Matthew Gibfried  and
George T. Grossberg
Matthew Gibfried
Affiliation:
Saint Louis University School of Medicine, Missouri
George T. Grossberg
Affiliation:
Saint Louis University School of Medicine, Missouri
Get access

Summary

Extrapyramidal symptoms are movement disorders associated with antipsychotics and include acute dystonias, akathisia, Parkinsonism, tardive dyskinesia, and neuroleptic malignant syndrome. Antipsychotic-related Parkinsonism and akathisia are the most commonly encountered antipsychotic related movement disorders. Tardive dyskinesia occurs with long-term antipsychotic use and can be very impactful on quality of life. Treatment options exist for those with tardive dyskinesia dependent on antipsychotics.

Keywords

antipsychoticsmovement disordertardive dyskinesiaParkinsonismextrapyramidal symptomsEPSdystoniaakithesiavalbenazinetetrabenazine
Type
Chapter
Information
Clinical Case Studies in Long-Term Care Psychiatry
Navigating Common Mental Health Challenges in Geriatric Care
 , pp. 62 - 67
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Stryjer, R., Rosenzcwaig, S., Bar, F., Ulman, A. M., Weizman, A., & Spivak, B. (2010). Trazodone for the treatment of neuroleptic-induced acute akathisia: A placebo-controlled, double-blind, crossover study. Clinical Neuropharmacology, 33, 219–222.CrossRefGoogle ScholarPubMed
Estevez-Fraga, C., Zeun, P., & López-Sendón Moreno, J. L. (2018). Current methods for the treatment and prevention of drug-induced Parkinsonism and tardive dyskinesia in the elderly. Drugs Aging, 35, 959–971. doi: 10.1007/s40266-018-0590-y.CrossRefGoogle ScholarPubMed
Shin, W., & Chung, S. J. (2012). Drug-induced Parkinsonism. Journal of Clinical Neurology (Seoul, Korea), 8 (1), 15–21. https://doi.org/10.3988/jcn.2012.8.1.15CrossRefGoogle ScholarPubMed
Solmi, M., Pigato, G., Kane, J. M., & Correll, C. U. (2018). Clinical risk factors for the development of tardive dyskinesia. Journal of Neurological Sciences, 389, 21–27.CrossRefGoogle ScholarPubMed
Luo, R., Bozigian, H., Jimenez, R., & Loewen, G. (2017). Single dose and repeat once-daily dose safety, tolerability and pharmacokinetics of valbenazine in healthy male subjects. Psychopharmacology Bulletin, 47 (3), 44–52. www.ncbi.nlm.nih.gov/pmc/articles/PMC5546550/Google ScholarPubMed

Further Reading

Ali, T., Sisay, M., Tariku, M., Mekuria, A. N., & Desalew, A. (2021). Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. PLoS ONE, 16 (9). https://doi.org/10.1371/journal.pone.0257129CrossRefGoogle ScholarPubMed
Caroff, S. N. (2020). Recent advances in the pharmacology of tardive dyskinesia. Clinical Psychopharmacology and Neuroscience, 18 (4), 493–506. https://doi.org/10.9758/cpn.2020.18.4.493CrossRefGoogle ScholarPubMed
Duma, S. R., & Fung, V. S. (2019). Drug-induced movement disorders. Australian Prescriber, 42 (2), 56–61. https://doi.org/10.18773/austprescr.2019.014CrossRefGoogle ScholarPubMed
Poyurovsky, M., Bergman, J., Pashinian, A., & Weizman, A. (2014). Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. International Clinical Psychopharmacology, 29, 296–298.CrossRefGoogle ScholarPubMed
Poyurovsky, M., & Weizman, A. (2018). Very low-dose mirtazapine (7.5 mg) in treatment of acute antipsychotic-associated akathisia. Journal of Clinical Psychopharmacology, 38, 609–611.CrossRefGoogle ScholarPubMed
Ricciardi, L., Pringsheim, T., Barnes, R. E., Martino, D., Gardner, D., Remington, G., Addington, D., Morgante, F., Poole, N., Carson, A., & Edwards, M. (2019). Treatment recommendations for tardive dyskinesia. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 64 (6), 388–399. https://doi.org/10.1177/0706743719828968CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×